STE STERIS plc (Ireland) Ordinary Shares

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.9% gain over the past six months, beating the S&P 500 by 25.5 percentage points.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

STERIS has trailed the broader market over the past year, while Wall Street analysts remain cautiously optimistic about the company’s future prospects.

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

STERIS stock has delivered a positive 11.2% total return over the past five years, yet current checks suggest the shares now trade close to a fair level rather than offering an obvious discount. The intrinsic value estimate from a Discounted Cash Flow (DCF) framework is slightly below the recent market price, and the broader valuation tools also lean toward STERIS being on the expensive side. Over five years, STERIS has returned 11.2%, which points to modest long term gains rather than a...

Conference appearance puts STERIS (STE) in the spotlight STERIS (STE) is drawing investor attention after confirming it will participate in the Morgan Stanley Healthcare Conference in New York on September 15, 2026, with CEO Dan Carestio scheduled to present. STERIS shares trade at US$229.65 after a small pullback in the past week, while the 90 day share price return of 9.26% points to building momentum that contrasts with a year to date share price decline of 8.15% and a 1 year total...

STERIS has lagged behind the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.

STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

Over the past six months, STERIS’s shares (currently trading at $232.53) have posted a disappointing 7.4% loss, well below the S&P 500’s 12.9% gain. This might have investors contemplating their next move.

ECL's 12.2% three-month rally is backed by High-Tech, Digital and Life Sciences growth, firmer pricing and a higher 2026 earnings outlook.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q2, starting with STERIS (NYSE:STE).

STERIS (NYSE:STE) reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina. Total reported revenue increased 7% from th

STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.

Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.

The Dublin-based company plans to relocate some existing U.S. operations to the new 600,000-square-foot campus in the coming years.

The mystery behind “Project Sol” has been revealed. Global healthcare company STERIS will build a $600 million manufacturing, research and distribution campus in Sanford, bringing at least 335 jobs to Lee County in what local leaders say is the largest economic development project in the county’s history. Gov. Josh Stein, and the Sanford Area Growth Alliance, announced Wednesday that STERIS ...